The U.S. Department of Energy’s January 2026 enrichment awards are the clearest signal yet that Washington intends to rebuild a domestic fuel chain. DOE spread roughly $2.7 billion across three $900 million task orders: Centrus for HALEU at Piketon, Ohio; General Matter for HALEU at Paducah, Kentucky; and Orano for conventional low-enriched uranium at Oak Ridge, Tennessee.

Milestones, not upfront cash

The awards are milestone-based. Money arrives as targets are met rather than upfront, a structure meant to protect taxpayers but one that also stretches timelines. That matters because the U.S. has banned imports of Russian enriched uranium, with waiver authority ending at the start of 2028 and the prohibition running to 2040. Russia currently supplies essentially all commercially available HALEU, so the gap between policy and production is the central risk.

HALEU is uranium enriched to between 5% and 20% uranium-235, denser than the fuel used by today’s commercial fleet and required by most advanced reactor designs.

Centrus is furthest along, but not commercial yet

Centrus has run a licensed centrifuge cascade at Piketon since late 2023 and has shipped its first new centrifuge for a multibillion-dollar expansion. Its first new commercial HALEU capacity is targeted for 2029. That is the nearest-term commercial HALEU milestone among the DOE awardees, but it is still three years away and depends on continued execution.

General Matter and Orano face licensing

General Matter’s NRC application was accepted for review only in late October, and the company plans a roughly $1.5 billion plant. Orano’s roughly $5 billion Project IKE near Oak Ridge is still in licensing; its application was accepted for accelerated review in May, with first supply not promised until the early 2030s. Those schedules show how much of the $2.7 billion is about future capacity rather than current fuel.

The market test is whether 2029 aligns Centrus’s first commercial HALEU with advanced reactors’ readiness to load fuel. If reactors slip, the capacity could become stranded in an unformed market. Listed Centrus has already fallen 70% amid delayed milestones, a reminder that policy support does not eliminate execution risk.

This article was assisted by AI analysis. Please refer to the original source for official information.